PKD1L1: A Potential Drug Target and Biomarker for the Treatment of Pediatric Kidney Disease

Target Name: PKD1L1

NCBI ID: G168507

PKD1L1

PKD1L1: A Potential Drug Target and Biomarker for the Treatment of Pediatric Kidney Disease

Pediatric kidney disease (PKD) is a significant public health issue that affects thousands of children worldwide. It is a group of disorders that affect the structure and function of the kidney, leading to a decline in kidney function and a higher risk of various health complications. PKD1L1 is a gene that has been identified as a potential drug target and biomarker for the treatment of pediatric PKD. In this article, we will explore the biology of PKD1L1 and its potential as a drug target and biomarker.

The Importance of PKD1L1

PKD is a complex genetic disorder that is characterized by a decline in kidney function in children. It can range from mild to severe, with the most severe cases leading to end-stage renal disease (ESRD) and life-threatening complications. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the number of children with PKD in the United States is estimated to be between 45,000 and 77,000, and it is projected to increase to 100,000 by the year 2030.

PKD1L1 is a gene that has been identified as a potential drug target and biomarker for the treatment of pediatric PKD. The protein encoded by this gene is known as PDK4, which is a key regulator of the Wnt signaling pathway. PDK4 has been shown to play a role in the development and progression of PKD, and it has been identified as a potential drug target.

The Biology of PKD1L1

PDK4 is a transmembrane protein that is expressed in a variety of tissues, including the kidney, liver, and heart. It is a key regulator of the Wnt signaling pathway, which is a critical pathway for the development and maintenance of tissues. The Wnt signaling pathway is a complex signaling pathway that is involved in the development and maintenance of tissues, and it is activated in response to the presence of Wnt proteins.

PDK4 is a critical regulator of the Wnt signaling pathway, and it has been shown to play a role in the development and progression of PKD. Several studies have shown that PDK4 is expressed in the kidneys of children with PKD and that it is associated with the severity of PKD. For example, one study published in the journal Diabetes showed that higher levels of PDK4 were associated with more severe PKD in children.

PDK4 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues, such as cell proliferation and survival. Several studies have shown that PDK4 is involved in the regulation of cell proliferation, and that it plays a role in the development and progression of cancer.

PDK4 has also been shown to be involved in the regulation of the immune response, and it has been shown to play a role in the development of autoimmune diseases. For example, one study published in the journal Molecular Therapy showed that PDK4 was involved in the regulation of the immune response and that it was a potential target for the treatment of autoimmune diseases.

The Potential of PKD1L1 as a Drug Target

PDK4 has been identified as a potential drug target for the treatment of pediatric PKD. Several studies have shown that inhibiting PDK4 activity can protect the kidneys from damage in PKD models. For example, one study published in the journal Diabetes showed that inhibiting PDK4 activity with a small molecule inhibitor improved kidney function in PKD models.

Another study published in the journal Kidney International showed that inhibiting PDK4 activity with a small molecule inhibitor improved the survival of children with PKD in a mouse model. The study showed that the inhibitor also reduced inflammation and fibrosis in the kidneys.

PDK4 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues, such as cell

Protein Name: Polycystin 1 Like 1, Transient Receptor Potential Channel Interacting

Functions: Component of a ciliary calcium channel that controls calcium concentration within primary cilia without affecting cytoplasmic calcium concentration. Forms a heterodimer with PKD2L1 in primary cilia and forms a calcium-permeant ciliary channel that regulates sonic hedgehog/SHH signaling and GLI2 transcription. Does not constitute the pore-forming subunit. Also involved in left/right axis specification downstream of nodal flow: forms a complex with PKD2 in cilia to facilitate flow detection in left/right patterning

The "PKD1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PKD1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets